Mylan settlement ‘irresponsible,’ says West Virginia Attorney General

Mylan settlement ‘irresponsible,’ says West Virginia Attorney General

The $465 million settlement over claims Mylan profited off an improper classification of its EpiPen autoinjector isn’t good enough, according to West Virginia Attorney General Patrick Morrissey.

Morrissey wrote a letter to the U.S. Department of Justice asking it not to finalize the settlement. He labeled it a “sweetheart” deal for Mylan after EpiPen was classified for years as a generic drug, reducing the quarterly CMS rebates Mylan owed to 13 percent instead of the 23 percent for brand-name drugs.

Morrissey said Mylan may owe as much as $700 million to Medicaid.

“While Mylan executives and shareholders would be winners, it is a losing proposition for taxpayers who fund Medicaid and the countless families who rely on EpiPen and are beholden to Mylan’s skyrocketing greed,” he wrote. “The people are fed up with such arrangements, and frankly, they should be. West Virginia deserves better.”

If the DOJ finalizes the settlement, Morrissey said he’ll urge the West Virginia Department of Health and Human Resources to opt out.

 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.